{"id":"W4389487695","doi":"10.1016/j.iotech.2023.100587","title":"115TiP MDT-BRIDGE: A phase II study of neoadjuvant durvalumab (D) + chemotherapy (CT) followed by either surgery and adjuvant D or chemoradiotherapy (CRT) and consolidation D in patients (pts) with resectable or borderline resectable stage IIB–IIIB NSCLC","year":2023,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Medical Imaging Techniques and Applications","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University","funders":"Genentech; LEO Pharma; Aptitude Health; European Society for Medical Oncology; Novocure; Regeneron Pharmaceuticals; Gilead Sciences; Ipsen; BeiGene; Daiichi Sankyo Europe; Sanofi; Amgen; Pfizer; Les Laboratories Pierre Fabre; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Neoadjuvant therapy; Internal medicine; Durvalumab; Oncology; Stage (stratigraphy); Chemotherapy; Radiology; Cancer; Immunotherapy; Pembrolizumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000928574,0.0003749014,0.001409794,0.0008827444,0.0002168474,0.00001717647,0.0002568831,0.0003451153,0.0002706915],"category_scores_gemma":[0.0004911989,0.0002712495,0.00004537799,0.001930451,0.0007768781,0.0001257845,0.0001979359,0.0005873294,0.000002758647],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002005076,"about_ca_system_score_gemma":0.0004550098,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006466322,"about_ca_topic_score_gemma":0.0003793462,"domain_scores_codex":[0.9972082,0.0001518114,0.0009045836,0.0007552671,0.0003270838,0.0006530833],"domain_scores_gemma":[0.9979573,0.0004286183,0.0004241843,0.0008361032,0.0002234758,0.0001302739],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.03940162,0.02653252,0.2526815,0.0004500114,0.001010156,0.001001204,0.002987511,0.000003847956,0.1949484,0.0001706906,0.07672279,0.4040897],"study_design_scores_gemma":[0.3502462,0.1605795,0.0629328,0.002030266,0.000847036,0.001399163,0.0108842,0.007078195,0.1248744,0.000519812,0.275728,0.002880472],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9891118,0.0007545663,0.000186865,0.006473846,0.00005979641,0.00281676,0.00004928015,0.0004799085,0.00006722],"genre_scores_gemma":[0.9932787,0.002219172,0.001566126,0.0003488502,0.00002297271,0.0008599836,0.0001527589,0.00009160405,0.001459816],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4012092,"threshold_uncertainty_score":0.999974,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02619642708077443,"score_gpt":0.3546546211225938,"score_spread":0.3284581940418194,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}